AzTrials
AzTrials

Breast CancerHOBBITNCT04091542

Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment

A study testing Optiflow/Ventilator in people with Breast Cancer, run by University Hospital, Ghent at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

With the HOBBIT trial, the investigators want to develop a technology that allows volunteers to hold their breath for a long time. This technique will then be taught to patients with breast cancer to be able to hold their breath long-term during the irradiation. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer
What is being tested?
Optiflow/Ventilator
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteBelgium
Study dates
15 Mar 2019to 22 Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Female
  • Volunteer
  • Age ≥ 18 years
  • Karnofsky index of at least 90
  • Single DIBH of at least twenty seconds without assistance
  • Informed consent obtained, signed and dated before specific protocol procedures

Who cannot join

  • Pregnant women
  • Volunteers above WHO Obesity class II (BMI>35kg/m²)
  • Subjects on oxygen treatment during day or night
  • COPD or Asthma patients
  • Volunteers with pulmonary hypertension
  • New York Heart Association functional classification (NYHA) of 2 or less
Show all 14Show fewer
  • Personal history of cerebrovascular disease, aortic disease, coronary artery disease or myocardial disease
  • Treatment with antihypertensive medication
  • Missing more than three teeth without use of a prosthesis
  • Gastric tube present
  • Smoking
  • Previous breath-holding experience (e.g. diver, etc.)
  • Anxiety symptoms grade 1 or higher according to CTCAE v.5
  • Mental condition rendering the volunteer unable to understand the nature, scope and possible consequences of the study

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Hospital - Radiotherapy Department

    Ghent, 9000

Other trials in Belgium

About this study

Official title: Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment (HOBBIT): Development of Support Technique to Prolong Breath Hold Time During Radiotherapy

With the HOBBIT trial, the investigators want to develop a technology that allows volunteers to hold their breath for a long time. This technique will then be taught to patients with breast cancer to be able to hold their breath long-term during the irradiation. After all, research has shown that the heart is in a better position when the patient enters her breath after a deep inhalation, as a result of which there is less unwanted radiation of the heart. To develop this technique the investigators use healthy volunteers, who are asked several times to hold their breath as long as comfortable. Before the respiratory arrest the investigators allow these volunteers to hyperventilate, administer oxygen and cause hyperinflation of the lungs.

The volunteers come back four times, on four consecutive days. The first day they receive a short training. Afterwards oxygen is administered for a few minutes while the volunteers are asked to hyperventilate. Afterwards, by using the learned technique, they must hold their breath for as long as possible, comfortably. They should hold their breath 3 times in total with a short break in between. The following days there is always a change in the preparation protocol, compared to the previous study. Different parameters in the protocol will be changed for different groups of volunteers, this is based on randomization. In this way the effect of different parameters in the preparation of the AHS can be investigated. The investigators will use this information to develop a new protocol for extending the duration of breathing to two minutes and thirty seconds for use during radiotherapy treatment. The method for finding the optimal technique is iterative optimization. This method follows a process of development, testing, feedback and redevelopment cycles. Iteratively, these cycles of development use the prior research to further elaborate the most promising discoveries and drop paths that do not produce the desired result. During the development The investigators listen to the input of different people: doctors, nurses, support staff, engineers and the participants, to guarantee the usability of the technique on the radiotherapy device. Once the researchers think they have found a solution that meets all the conditions, a group of untrained volunteers are asked to implement the technique. With this the investigators validate the technique for later use in breast cancer patients.

Read the detailed description

Radiotherapy (RT) has an established role in breast cancer, complementing surgery and systemic therapies to prevent recurrences and improve survival. Long-Term follow-up shows that the beneficial effect on survival is weakened by radiation-induced cardiac and lung cancer mortality, especially in patients with left sided breast cancer or requiring irradiation of regional lymph nodes. Cardiac toxicity is of major concern because many patients receive cardiotoxic systemic treatments like anthracyclines and trastuzumab. Dose and volume of the heart exposed to radiation correlate with severity of cardiac toxicity. The heart dose-volume parameters are highest for patients receiving left-side radiotherapy especially if irradiation of the internal mammary lymph nodes is performed. Risk of (fatal) ischemic heart attack increases linearly with mean heart dose with no known dose threshold. In patients who receive left-side local treatment, heart dose is decreased by using prone positioning or deep-inspiration breath hold (DIBH), or a combination of both.

Previous research has shown that the heart shifts to an anatomical more favorable position in DIBH, away from the breast, chest wall and internal mammary lymph nodes, reducing heart dose. This advantage remains in prone positioning. The goal is to prolong the duration of a single DIBH, to create a long-DIBH (L-DIBH). Possible advantages are better positioning of the patient, execution of technically more difficult procedures and inclusion of regional lymph node (locoregional) irradiation. Most patients can't sustain a DIBH long enough to perform simulation with computed tomography (CT) and delineation during DIBH, so delineation of the laser lines during CT-simulation is performed on the shallow breathing (SB) scan. During positioning of the patient on the radiotherapy machine, a daily cone-beam CT (CBCT) is performed. The duration of this CBCT is 40 seconds, maintaining DIBH during this period is also hard for most patients. So currently the positioning at the moment of treatment is based on the SB CT-scan, whilst the DIBH CT-scan is used for treatment. This could potentially induce suboptimal positioning. Breath hold during CBCT positioning and CT-simulation and delineation could minimize shifts in treatment position. The current DIBH schedules for whole breast cancer radiotherapy without inclusion of the lymph nodes, use between three and six DIBHs of 12 to 18 seconds. Longer DIBH could lead to less DIBHs and faster treatment execution, which is especially important when the lymph nodes are included in the target volumes. Locoregional irradiation, including the lymph nodes, requires between 10 and 14 DIBHs of 15-30 seconds which leads to a total treatment time of around 5 minutes. This represents a substantial physical and mental effort for all but the most able patients.

This research, the first phase of the Hyperventilation Oxygenation Breath hold in Breast cancer Irradiation Treatment (HOBBIT) trail, will focus on finding a technique to assist patients to maintain a long DIBH (L-DIBH) during radiotherapy. Other research has shown a potential increase in duration of breath hold and reduction in rest time between DIBHs using oxygen in combination with hyperventilation. There is a safe way to prolong DIBH to at least 5 minutes. However, the technique requires a long training period for the patient, and 15 minutes of mechanical ventilation before each treatment session, making the technique very time consuming and resource intensive. The investigators hope to simplify the technique by allowing patients to do multiple L-DIBHs during the 5 minutes of treatment time. The investigators found from preliminary tests that using shorter L-DIBHs has several advantages, firstly pre-oxygenation and induction of hypocapnia can be achieved in a shorter time, secondly the duration of training is reduced, and thirdly a the costs are reduced.

Increase in blood pressure is the main risk of L-DIBH. No adverse events of L-DIBH have been reported. In order to minimize the risks during testing, this research project was developed in collaboration with the anesthesiology department, to ensure safety of the participants during L-DIBH. For all subjects, vital parameters will be continuously monitored by medical staff. Safety boundaries are in place which subjects are not allowed to cross during L-DIBH.

The aim of this research is to develop a new and easy technique for L-DIBH in prone and supine position, feasible for daily use at our radiotherapy department. The purpose of the technique is to allow locoregional treatment using a reasonable amount of L-DIBHs, increase patient positioning and accuracy of radiation treatment, and further significantly reduce heart toxicity for left sided cancer patients. The HOBBIT trial includes multiple phases. The first phase is performed on healthy volunteers, different support techniques to prolong DIBH will be tested. In the second phase the most optimal techniques to perform a L-DIBH will be validated on breast cancer patients. Around 40 volunteers will be included in the first phase of the HOBBIT trail, the final amount of volunteers depends on the amount of testing needed to find a technique which fulfills all criteria for phase two. The second phase of the HOBBIT trail will include breast cancer patients treated at our radiotherapy center. The expectations from previous research is that the investigators will see a similar increase in DIBH time, compared to healthy volunteers. The final goal is the use of the technique during locoregional radiation therapy at the University Hospital of Ghent.

Conditions
Breast Cancer
Being tested
Optiflow/Ventilator
Keywords
breath hold, hyperventilation, oxygenation
Medical subject headings
Breast Neoplasms, Hyperventilation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Optiflow/VentilatorDevice

    Participants will have 2 days with optiflow, 2 days with ventilator.

Study groups in NCT04091542
Study groupRoleWhat they receive
FiO2 group 1ExperimentalFiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
Receives: Device: Optiflow/Ventilator
FiO2 group 2ExperimentalFiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
Receives: Device: Optiflow/Ventilator
Duration 1ExperimentalIn duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
Receives: Device: Optiflow/Ventilator
Duration 2ExperimentalIn duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
Receives: Device: Optiflow/Ventilator
respiratory rate 1ExperimentalIn the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
Receives: Device: Optiflow/Ventilator
respiratory rate 2ExperimentalIn the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
Receives: Device: Optiflow/Ventilator
Position 1ExperimentalThe position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
Receives: Device: Optiflow/Ventilator
Position 2ExperimentalThe position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
Receives: Device: Optiflow/Ventilator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. conditions for a technique for L-DIBHs of more than two minutes thirty seconds

    duration of preparation/hyperventilation and oxygenation

    Measured: 2 years

Secondary outcomes (21)
  1. Oxygen saturation

    fraction of [oxygen]-saturated hemoglobin relative to total hemoglobin in the blood

    Measured: 1 year

  2. heart rate

    speed of the heartbeat measured by the number of contractions (beats) of the heart per minute (bpm)

    Measured: 1 year

  3. diastolic and systolic blood pressure

    the pressure of circulating blood on the walls of blood vessels

    Measured: 1 year

  4. EtCO2

    patient's end-tidal CO2

    Measured: 1 year

  5. average L-DIBH time

    measured in minutes and seconds

    Measured: 1 year

  6. average time needed for SpO2 to recover to normal

    measured in minutes and seconds

    Measured: 1 year

  7. average total time needed to perform three L-DIBHs consequently

    measured in minutes and seconds

    Measured: 1 year

  8. Measurement of linear anteroposterior displacement

    measured in millimetres

    Measured: 1 year

  9. dizziness

    an impairment in spatial perception and stability.

    Measured: 1 year

  10. fear

    a feeling induced by perceived danger or threat that occurs in certain types of organisms, which causes a change in metabolic and organ functions and ultimately a change in behavior, such as fleeing, hiding, or freezing from perceived traumatic events

    Measured: 1 year

  11. headache

    the symptom of pain anywhere in the region of the head or neck

    Measured: 1 year

  12. syncope

    syncope

    Measured: 1 year

  13. coughing

    a sudden, and often repetitively occurring, protective reflex which helps to clear the large breathing passages from fluids, irritants, foreign particles and microbes

    Measured: 1 year

  14. dyspnea

    the feeling that one cannot breathe well enough

    Measured: 1 year

  15. nausea

    an unpleasant, diffuse sensation of unease and discomfort, often perceived as an urge to vomit

    Measured: 1 year

  16. vomiting

    the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose

    Measured: 1 year

  17. itching

    a sensation that causes the desire or reflex to scratch

    Measured: 1 year

  18. pain

    a distressing feeling often caused by intense or damaging stimuli

    Measured: 1 year

  19. palpitations

    the perceived abnormality of the heartbeat characterized by awareness of cardiac muscle contractions in the chest, which is further characterized by the hard, fast and/or irregular beatings of the heart

    Measured: 1 year

  20. blurred vision

    an ocular symptom

    Measured: 1 year

  21. muscle cramps

    a sudden, involuntary muscle contraction or over-shortening; while generally temporary and non-damaging, they can cause significant pain, and a paralysis-like immobility of the affected muscle

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2019
  2. Study start15 Mar 2019
  3. Primary completion31 Dec 2019
  4. Study completion22 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04091542
Sponsor's protocol ID
EC2019/0127
Acronym
HOBBIT
Status last verified
Jan 2023
First submitted
22 Mar 2019
Last updated
4 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Optiflow/Ventilator in people with Breast Cancer, run by University Hospital, Ghent at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

conditions for a technique for L-DIBHs of more than two minutes thirty seconds (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in